Charles River Laboratories | CRL - Gross Profit On Sales

Stock Price
166.79
Daily Change
-4.44 -2.59%
Monthly
4.43%
Yearly
42.20%
Q2 Forecast
166.17

Charles River Laboratories reported $271.96M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Agilent USD 946M 44M Dec/2025
Align Technology USD 683.59M 44.39M Dec/2025
Bio-Rad Laboratories USD 343.4M 1.9M Sep/2025
Bruker USD 449.2M 69.8M Dec/2025
Cardinal Health USD 2.4B 78M Dec/2025
Charles River Laboratories USD 271.96M 39.43M Dec/2025
Cigna USD 56.45B 50.29B Sep/2025
Concord Medical Services Hldg CNY -37.42M 26.25M Jun/2023
CVS Health USD 13.57B 239M Dec/2025
Danaher USD 3.59B 375M Mar/2026
Dentsply International USD 443M 2M Dec/2025
Elevance Health USD 11.68B 889M Dec/2025
Galapagos EUR -13.57M 74.82M Sep/2025
Humana USD 4.82B 754M Jun/2025
Illumina USD 759M 26M Dec/2025
Incyte USD 1.17B 217.51M Mar/2026
Intrexon USD -297K 167K Jun/2024
IQVIA Holdings USD 1.12B 32M Dec/2025
Laboratory Of America USD 993.2M 31.9M Dec/2025
Lonza CHF 1.29B 248M Jun/2025
McKesson USD 3.68B 143M Dec/2025
Merck EUR 2.96B 252M Dec/2025
Mettler Toledo International USD 675.44M 65.98M Dec/2025
Novartis USD 10.25B 570M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Quest Diagnostics USD 906M 33M Mar/2026
Revvity USD 421.66M 47.06M Dec/2025
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025
UnitedHealth USD 18.49B 2.14B Dec/2025
Veradigm USD 83.44M 3.95M Sep/2022
Waters USD 557.42M 97.44M Dec/2025
West Pharmaceutical Services USD 296.4M 7.5M Mar/2026